MariMedMRMD +4.75% OCF Margin % is 2.40% as of Mar. 2026, which is 53% below its 10-year median of 5.07. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, MariMed ranks worse than 62.04% on this metric.
The historical rank and industry rank for MariMed's OCF Margin % or its related term are showing as below:
MRMD'
s OCF Margin % Range Over the Past 10 Years
Min: -52.93 Med: 5.07 Max: 29.52
Current: 4.55
During the past 13 years, the highest OCF Margin % of MariMed was 29.52%. The lowest was -52.93%. And the median was 5.07%.
MRMD's OCF Margin % is ranked worse than 62.04% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs MRMD: 4.55
MariMed OCF Margin % Related Terms
MariMed OCF Margin % Historical Data
* Premium members only.
The historical data trend for MariMed's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's OCF Margin % distribution charts can be found below:
* The bar in red indicates where MariMed's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed (MRMD) has a OCF Margin % of 2.40% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on MariMed and its competitors. This is 53% below median its historical median of 5.07. According to the industry distribution chart, MariMed ranks #595 out of 959 companies in the Drug Manufacturers industry, placing it in the top 62%.
Is MariMed's OCF Margin % too high?
MariMed's current OCF Margin % of 2.40% is 53% below median its 10-year median of 5.07. The Drug Manufacturers industry median OCF Margin % is 9.94. MariMed's value of 2.40% is 75.9% below this industry median. Based on the distribution chart, MariMed ranks #595 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does MariMed's OCF Margin % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #595 out of 959 companies for OCF Margin %. This places MariMed in the lower half of its industry. The industry median OCF Margin % is 9.94. MariMed's value of 2.40% is 75.9% below this benchmark. While the company's 10-year median is 5.07 vs. the industry median of 9.94, MariMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current OCF Margin % of 2.40% is 75.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current OCF Margin % is 2.40%, which is 53% below median its own 10-year median of 5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 54.5% below its estimated fair value. The current OCF Margin % is 2.40%, which is 53% below median its 10-year median of 5.07 and 75.9% below the Drug Manufacturers industry median of 9.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For MariMed (MRMD), the current OCF Margin % is 2.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 